{"id":"W2810093122","doi":"10.1007/s10637-017-0455-y","title":"Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"erratum","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"","keywords":"Calcium channel; TRPV6; Calcium; Medicine; Phase (matter); Pharmacology; Internal medicine; Chemistry; Calcium metabolism","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002546771,0.0007194415,0.001053016,0.0009212352,0.0003634214,0.0001081054,0.001022654,0.000378055,0.00004574672],"category_scores_gemma":[0.0006624417,0.0006368319,0.0001202101,0.0007401211,0.0003868109,0.0004703583,0.0002770269,0.001212966,0.00003191667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002613044,"about_ca_system_score_gemma":0.001170465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000812194,"about_ca_topic_score_gemma":0.0008177335,"domain_scores_codex":[0.9950157,0.0001841464,0.001142015,0.001321237,0.001614713,0.000722193],"domain_scores_gemma":[0.9975092,0.0001246107,0.001012868,0.0006017962,0.0002202106,0.0005312785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0009841508,0.009295697,0.00293563,0.0004793939,0.00005728847,0.0001617291,0.02891534,0.009048736,0.003737775,0.0002178606,0.9436403,0.0005261235],"study_design_scores_gemma":[0.2700201,0.06546538,0.1318195,0.04804507,0.0006028633,0.00005255642,0.01191378,0.007546725,0.248732,0.03188071,0.161293,0.02262829],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814909,0.00003399297,0.000005077677,0.0009458661,0.01165634,0.002510244,0.0002098194,0.00005845301,0.00308931],"genre_scores_gemma":[0.9642248,0.000007515921,0.00004554407,0.0004653077,0.001110529,0.0001671344,0.000295231,0.0001220229,0.03356187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7823473,"threshold_uncertainty_score":0.9996083,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03240136017940257,"score_gpt":0.310777729779994,"score_spread":0.2783763696005914,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}